Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023

from Medical Digest & Congress Report · host Medical Congress News

Professor Laura Locati highlights findings from phase 3 LIBRETTO-531 trial, that has demonstrated the superiority of selpercatinib, a highly selective RET kinase inhibitor, over approved multikinase inhibitors in people with advanced RET-mutant medullary thyroid cancer. Video: https://medicaldigest.org/scientific-contents/interview:selpercatinib-improves-outcomes-ret-mutant-medullary-thyroid-cancer

Episode metadata supplied by the publisher feed · Published Oct 31, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023

0:00 6:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on October 31, 2023.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!